Diagnostic Technologies (US) sues Dianon Systems for $10 million:
This article was originally published in Clinica
Executive Summary
Diagnostic Technologies (US) is suing Dianon Systems (US) for breach of contract, reliance and interference with business advantage. The suit comes after Dianon decided not to enter into an agreement with Diagnostic for the development and licensing of technology relating to an assay for identifying pre-term delivery, pre-eclampsia toxaemia and intra-uterine growth retardation. Dianon chairman Richard Sandberg confirms that the claims, filed in the Central California District Court, seek over $10 million in damages but says they are without merit.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.